Myc 102

Drug Profile

Myc 102

Alternative Names: Myc102; Mycobactovir

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LTN Pharm; TGV-Laboratories
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumonia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Mycoses
  • Phase II/III Dermatomycoses
  • Preclinical Candidiasis
  • Research Aspergillosis; Cryptococcosis; Onychomycosis; Pneumonia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumonia in Russia (Inhalation)
  • 20 Jan 2016 Phase-III clinical trials in Mycoses in Russia (PO) before January 2016 (TGV-Laboratories Pipeline, January 2016)
  • 08 Apr 2015 Early research in Candidiasis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top